Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Key facts

Sponsor

AGO Study Group

Principal Investigator

Philipp Harter, MD, PhD

KEM Essen | Evang. Kliniken Essen-Mitte gGmbH

Intervention

Carboplatin(drug)

Enrollment

970 enrolled

Eligibility

18 years · FEMALE

Timeline

2022 – 2031

Study locations (30)

• Klinikum St. Marien Amberg, Amberg, Germany
• Klinikum Augsburg, Augsburg, Germany
• Hochtaunus-Kliniken, Bad Homburg, Germany
• Helios Klinikum Berlin-Buch, Berlin, Germany
• Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany
• Städt. Klinikum Brandenburg, Brandenburg an der Havel, Germany
• Klinikum Bremen Mitte, Bremen, Germany
• Klinikum Chemnitz, Chemnitz, Germany
• St. Elisabeth-Krankenhaus Köln-Hohenlind, Cologne, Germany
• Klinikum Dortmund, Dortmund, Germany
• Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
• Florence-Nightingale-Krankenhaus Düsseldorf, Düsseldorf, Germany
• Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany
• KEM Essen | Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany
• Universitätsklinikum Essen, Essen, Germany
• +15 more locations on ClinicalTrials.gov

Collaborators

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07508306
  Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity
  Faculty of Medicine of Tunis
• RECRUITINGPHASE1NCT07524322
  Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  Regor Pharmaceuticals Inc.
• RECRUITINGPHASE1NCT06366490
  Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
  PhotonPharma, Inc.
• RECRUITINGPHASE1NCT07402915
  Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  AstraZeneca
• RECRUITINGNANCT07280312
  Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
  Mayo Clinic
• RECRUITINGPHASE2NCT07158021
  Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  University of Michigan Rogel Cancer Center
• RECRUITINGPHASE2NCT06971744
  Autophagy Maintenance (AUTOMAIN)
  Medical University of South Carolina
• RECRUITINGPHASE3NCT06963268
  Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)
  Instituto de Investigacion Sanitaria La Fe

See all trials for Malignant epithelial tumor of ovary →